Immunomedics, inc. (IMMU)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenues:
Total revenues

0

295

0

0

0

0

0

386

482

597

690

641

1,323

384

741

931

899

671

730

2,395

1,182

1,002

1,071

1,186

1,154

1,202

5,497

1,361

1,736

812

1,051

963

970

29,655

1,144

11,115

1,097

1,003

1,493

Costs and Expenses:
Costs of goods sold

-

-

0

0

-

0

0

0

47

496

70

45

135

46

255

698

337

64

58

46

72

68

76

68

90

103

77

110

93

91

96

106

90

134

95

104

98

107

109

Costs of license fee and other revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,189

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

62,428

74,818

68,958

52,923

58,172

55,648

38,239

27,603

28,843

25,495

17,342

12,010

12,491

12,748

14,525

13,018

13,298

14,261

12,913

11,593

10,385

10,364

9,392

10,781

8,141

7,243

7,514

7,048

8,113

6,425

6,793

6,135

6,892

6,415

4,812

5,891

7,037

5,762

5,845

Sales and marketing

8,067

6,299

5,933

6,346

7,881

14,035

5,799

3,039

2,366

1,189

226

169

302

185

215

248

248

386

143

79

285

174

228

246

243

424

218

212

221

187

204

200

194

239

211

246

224

175

182

General and administrative

11,473

10,429

11,880

7,899

13,595

17,683

13,131

22,139

6,854

2,842

4,650

15,139

10,514

2,763

691

1,602

1,580

1,655

1,724

1,863

1,564

1,856

3,819

2,305

2,200

2,042

1,732

1,667

1,500

1,713

1,272

1,504

1,399

1,690

1,167

1,834

1,749

1,474

2,057

Total costs and expenses

81,968

91,546

86,771

67,168

79,648

87,366

57,169

52,781

38,110

30,024

22,288

27,365

23,443

15,743

15,688

15,567

15,465

16,368

14,839

13,583

12,308

12,464

13,516

13,401

10,676

9,812

10,731

9,039

9,929

8,417

8,367

7,947

8,576

8,479

6,287

8,077

9,109

7,519

8,193

Operating loss

-81,968

-91,251

-86,771

-67,168

-79,648

-87,366

-57,169

-52,395

-37,628

-29,427

-21,598

-26,723

-22,120

-15,359

-14,946

-14,635

-14,566

-15,697

-14,108

-11,187

-11,125

-11,461

-12,444

-12,214

-9,521

-8,610

-5,233

-7,677

-8,193

-7,605

-7,316

-6,983

-7,606

21,175

-5,142

3,038

-8,012

-6,516

-6,699

Fair Value Adjustment of Warrants

-

-

0

0

-

-204

-1,200

58,900

-9,835

-26,768

86,378

-

28,336

7,230

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant related expenses

-

-

-

-

-

-

-

-

-

-

-

-

7,649

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

13,538

10,006

9,747

10,625

9,959

9,875

10,142

9,434

10,900

273

2,647

1,370

1,369

1,369

1,369

1,370

1,369

1,369

1,369

-

720

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Arbitration settlement, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,739

-

-

-

-

-

-

-

-

-

-

Insurance proceeds received

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,500

-

-

-

-

-

-

-

-

-

Qualifying Therapeutic Discovery Project Program

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,888

-

Gain on auction rate securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

413

-

-

Interest and other income

2,427

1,618

2,195

1,840

2,203

4,412

1,694

3,565

1,130

382

416

211

64

69

85

80

81

83

91

176

32

11

25

16

15

18

6

-132

1

1

139

1

-11

20

7

-285

21

251

252

Loss on induced exchanges of debt

-

-

-

-

-

-

-

-

-

-

-13,005

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other financing expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-346

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Insurance reimbursement

-

-

0

0

-

0

190

342

1,930

0

4,366

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency transaction gain, net

-

-

0

0

-

0

0

-101

75

23

84

140

91

-211

2

2

-38

6

-10

-30

28

11

-11

8

-25

12

5

-14

13

-66

29

-5

102

-106

22

2

48

-53

28

Loss before income tax

-93,079

-99,639

-94,323

-75,953

-87,404

-93,540

-64,209

-116,884

-35,558

-2,527

-118,762

-53,248

-59,320

-24,448

-16,228

-15,922

-15,893

-16,976

-15,396

-12,411

-11,784

-11,438

-12,430

-12,189

-9,532

-8,579

-5,221

-7,686

8,560

-5,169

-7,147

-6,987

-7,514

21,089

-5,112

3,074

-7,529

-3,429

-6,418

Income tax expense

0

0

0

0

0

0

0

156

0

-

0

-

-

-

-

2

-1,871

-3,204

19

16

3

26

11

6

1

-4

4

24

-19

19

19

-10

-216

422

13

-9

73

-1

46

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-93,079

-99,639

-94,323

-75,953

-87,404

-93,540

-64,209

-117,040

-35,558

-2,527

-118,762

-53,268

-59,320

-24,448

-16,228

-15,925

-14,021

-13,772

-15,416

-12,427

-11,788

-11,465

-12,442

-12,196

-9,533

-8,574

-5,226

-7,710

8,580

-5,189

-7,166

-6,977

-7,297

20,666

-5,126

3,083

-7,603

-3,427

-6,465

Net loss attributable to noncontrolling interest

-32

-31

-31

0

-67

-41

-40

-11

-12

-13

-17

-13

-14

-0

-31

-24

-25

-26

-22

-26

-32

-30

-32

-26

-28

-25

-25

-27

-27

-23

-25

-29

-31

-26

-26

-

-145

-

-

Net loss attributable to Immunomedics, Inc. stockholders

-93,047

-99,608

-94,292

-75,953

-87,337

-93,499

-64,169

-117,029

-35,546

-2,513

-118,745

-53,254

-59,306

-24,447

-16,197

-15,901

-13,996

-13,746

-15,393

-12,400

-11,756

-11,435

-12,410

-12,169

-9,505

-8,549

-5,200

-7,682

8,608

-5,166

-7,140

-6,948

-7,266

20,693

-5,100

3,111

-7,457

-3,427

-6,465

Loss per common share attributable to Immunomedics, Inc. stockholders:
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share)

-0.44

-0.49

-0.49

-0.40

-0.46

-0.50

-0.34

-0.68

-0.21

-0.02

-0.97

-0.52

-0.55

-0.23

-0.17

-0.16

-0.15

-0.15

-0.16

-0.13

-0.13

-0.12

-0.13

-0.15

-0.11

-0.10

-0.06

-

-

-0.07

-0.09

-

-

-

-0.07

-

-

-

-0.09

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

-

-

-

-0.10

0.27

-

-

-0.10

-0.05

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

-

-

-

-0.10

0.27

-

-

-0.10

-0.05

-

Weighted average shares used to calculate loss per common share:
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares)

213,247

199,690

191,981

191,745

191,052

190,171

186,937

171,124

166,054

154,486

122,550

109,763

107,839

104,657

95,883

95,071

94,748

94,664

94,595

93,652

93,351

93,157

93,098

89,063

83,340

83,174

82,947

-

-

75,671

75,610

-

-

-

75,435

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

78,195

-

-

-

75,490

75,458

-

-

75,317

75,289

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

78,447

-

-

-

75,490

75,964

-

-

75,317

75,289

-

Other comprehensive loss, net of tax:
Foreign currency translation adjustments

-9

33

-45

195

-9

-12

4

50

-66

-15

-73

-120

-52

73

37

-34

72

-54

17

76

-253

-79

-178

-23

3

47

72

45

-66

42

60

-116

60

-79

-178

-26

169

-31

150

Consolidated net (loss) income

-93,079

-99,639

-94,323

-75,953

-87,404

-93,540

-64,209

-117,040

-35,558

-2,527

-118,762

-53,268

-59,320

-24,448

-16,228

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,603

-3,427

-6,465

Unrealized loss on securities available for sale

-225

0

-191

0

-200

-5

15

54

10

-41

32

-56

5

-25

-32

16

90

-112

33

5

16

-5

-4

-10

-4

19

-4

-

-

-

-

-

-

-

-

0

-413

81

123

Other Comprehensive Income (Loss), Net of Tax

-234

33

-236

195

-209

-17

19

104

-56

-57

-41

-177

-46

48

4

-18

163

-167

51

82

-237

-85

-182

-34

-0

67

67

45

-66

42

60

-116

60

-79

-178

-26

-243

50

273

Net comprehensive (loss) income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,514

5,147

7,106

-

-

-20,587

5,305

-

-

-

-

Comprehensive loss

-93,313

-99,606

-94,559

-75,758

-87,613

-93,557

-64,190

-116,936

-35,614

-2,584

-118,803

-53,445

-59,367

-24,399

-16,224

-15,943

-13,857

-13,940

-15,364

-12,344

-12,025

-11,551

-12,625

-12,230

-9,534

-8,507

-5,158

-

-

23

25

7,298

-7,237

26

26

-

-7,847

-

-

Comprehensive loss attributable to noncontrolling interest

-32

-31

-31

0

-67

-41

-40

-11

-12

-13

-17

-13

-14

-0

-31

-24

-25

-26

-22

-26

-32

-30

-32

-26

-28

-25

-25

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to Immunomedics, Inc. stockholders

-93,281

-99,575

-94,528

-75,758

-87,546

-93,516

-64,150

-116,925

-35,602

-2,570

-118,786

-53,431

-59,352

-24,399

-16,193

-15,919

-13,832

-13,913

-15,342

-12,317

-11,993

-11,520

-12,593

-12,203

-9,506

-8,482

-5,133

-7,636

8,541

-5,124

-7,080

-7,064

-7,206

20,613

-5,279

3,085

-7,701

-3,377

-6,191

Product sales
Revenues

-

-

0

0

-

0

0

0

450

523

526

606

921

316

597

546

543

589

581

465

694

761

727

706

925

949

559

772

751

733

733

825

768

1,064

859

899

848

728

1,130

License fee and other revenues
Revenues

-

-

0

0

-

0

0

250

15

63

1

1

257

10

15

84

266

25

10

-

250

-

-

0

0

0

4,623

-

126

-

-

-

-

28,418

-

-

14

75

-

Research and development
Revenues

-

-

0

0

-

0

0

136

17

9

163

33

144

57

129

300

89

55

138

930

238

241

344

480

229

252

315

589

858

78

318

137

202

173

284

178

233

199

363